Skip to main content

Table 2 Clinical features of epilepsy among participants

From: Effect of long-term administration of clonazepam, carbamazepine, and valproate on cognitive, psychological, and personality changes in adult epilepsy: a case–control study

Variables Group 1
N = 35
N (%)
Group 2
N = 18
N (%)
Group 3
N = 31
N (%)
Group 4
N = 15
N (%)
Group 5
N = 40
N (%)
P value
Frequency of seizures
 Less than 6 times\month 35 (100%) 15 (83.3%) 28 (90.3%) 9 (60%) 32 (80%) 0.000*
 More than 6 times\month 0 (0%) 3 (16.7%) 3 (9.7%) 6 (40%) 8 (20%)  
Type of seizures
 Generalized 0 (0%) 18 (100%) 20 (70.9%) 15 (100%) 21 (52.5%) 0.000*
 Partial 35 (100%) 0 (0%) 5 (16.1%) 0 (0%) 19 (47.5%)  
 Absence 0 (0%) 0 (0%) 2 (6.5%) 0 (0%) 0 (0%)  
 Myoclonus 0 (0%) 0 (0%) 2 (6.5%) 0 (0%) 0 (0%)  
Duration of illness
 Less than 5 years 11 (31.4%) 1 (5.6%) 11 (35.5%) 0 (0%) 40 (100%) 0.001*
 5–10 years 18 (51.4%) 5 (27.8%) 10 (32.3%) 12 (80%) 0 (0%)  
More than 10 years 6 (17.1%) 12 (66.7%) 10 (32.3%) 3 (20%) 0 (0%)  
EEG changes
 Non-specific changes 27 (77.2%) 8 (44.4%) 19 (61.3%) 12 (80%) 14 (35%) 0.0003*
 Generalized 0 (0%) 10 (55.6%) 3 (9.7%) 3 (20%) 15 (37.5)  
Focal 8 (22.8%) 0 (0%) 9 (29%) 0 (0%) 11 (27.5%)  
 1. Temporal site 6 (17.1%) 0 (0%) 7 (22.5%) 0 (0%) 7 (17.5%)  
 2. Frontal site 2 (5.7%) 0 (0%) 2 (6.5%) 0 (0%) 4 (10%)  
  1. Group 1: carbamazepine, group 2: valproate, group 3: carbamazepine and clonazepam, group 4: valproate and clonazepam, group 5: epileptic patients without antiepileptic drugs (AEDs), *significant P value